SCHEMBL4856676

SCHEMBL4856676

CN1CCN(Cc2ccc3c(c2)NC(=O)c2ccc(B4OC(C)(C)C(C)(C)O4)cc2N3)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 2/20 0.40
KDR P35968 2/20 0.40
CHEK1 O14757 9/20 0.37
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36
CHKA P35790 2/20 0.36
LPL P06858 1/20 0.36
LIPG Q9Y5X9 1/20 0.36
PIM1 P11309 1/20 0.35
CSNK1D P48730 1/20 0.35
CHEK2 O96017 1/20 0.34
KIT P10721 1/20 0.34
MARK3 P27448 1/20 0.34
MAPK1 P28482 1/20 0.34
AKT1 P31749 1/20 0.34
MARK2 Q7KZI7 1/20 0.34
AURKB Q96GD4 1/20 0.34
TNKS O95271 1/20 0.34
PARP1 P09874 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4852354 0.84 CHEK1 (0.43) PDGFRBKDRCHEK1CHEK2KIT
SCHEMBL4858753 0.81 CHEK1 (0.41) CHEK1LPLLIPG
SCHEMBL4853657 0.80 CHEK1 (0.50) PDGFRBKDRCHEK1CHKALMNA
SCHEMBL4855604 0.79 CHEK1 (0.46) CHEK1LPLLIPGCHEK2KIT
SCHEMBL4856016 0.78 CHEK1 (0.49) KDRCHEK1LIPGCHEK2KIT
SCHEMBL4853578 0.77 ACVR1 (0.49) KDRCHEK1LPLLIPGMARK3
SCHEMBL429722 0.76 LMNA (0.53) CHKALPLLIPGLMNA
SCHEMBL4857019 0.76 CHEK1 (0.53) CHEK1PRMT5WDR77LPLLIPG
SCHEMBL4850618 0.75 CHEK1 (0.67) CHEK1CHEK2KITMARK3MAPK1
SCHEMBL722120 0.74 LPL (0.52) CHKALPLLIPGLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1606268-B1 5,10-DIHYDRO-11H-DIBENZO[B,E][1,4]DIAZEPIN-11-ONE AS KINASE INHIBITORS ABBVIE INC (US) 2015-05-20 EP disclosed
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US disclosed
US-20040254159-A1 Heterocyclic kinase inhibitors ABBOTT LABORATORIES 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254159-A1 Heterocyclic kinase inhibitors MAP3K20, MAP3K19, MAP3K1 PDGFRB 694/4885KDR 952/4885CHEK1 46/4885
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 PDGFRB 617/4885KDR 819/4885CHEK1 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.